Truist Financial Forecasts Strong Price Appreciation for Fresenius Medical Care (NYSE:FMS) Stock

Fresenius Medical Care (NYSE:FMS) had its price objective upped by equities research analysts at Truist Financial from $23.00 to $25.00 in a report released on Monday,Benzinga reports. The firm currently has a “hold” rating on the stock. Truist Financial’s price objective would indicate a potential upside of 11.71% from the stock’s current price.

A number of other equities analysts have also recently commented on the company. StockNews.com assumed coverage on Fresenius Medical Care in a report on Friday. They set a “strong-buy” rating for the company. Bank of America upgraded shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd. Finally, Berenberg Bank initiated coverage on shares of Fresenius Medical Care in a research note on Wednesday, November 6th. They set a “buy” rating and a $25.60 price objective for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $25.30.

Fresenius Medical Care Stock Performance

NYSE:FMS opened at $22.38 on Monday. The stock has a market capitalization of $13.13 billion, a PE ratio of 18.50, a P/E/G ratio of 0.96 and a beta of 0.92. The company has a fifty day moving average of $22.24 and a two-hundred day moving average of $20.67. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. Fresenius Medical Care has a fifty-two week low of $17.93 and a fifty-two week high of $24.31.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Allworth Financial LP raised its position in Fresenius Medical Care by 53.1% in the third quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock valued at $36,000 after purchasing an additional 581 shares during the period. Mercer Global Advisors Inc. ADV increased its position in shares of Fresenius Medical Care by 4.5% during the second quarter. Mercer Global Advisors Inc. ADV now owns 14,581 shares of the company’s stock valued at $278,000 after acquiring an additional 624 shares during the last quarter. MML Investors Services LLC raised its stake in shares of Fresenius Medical Care by 5.3% in the 3rd quarter. MML Investors Services LLC now owns 15,019 shares of the company’s stock valued at $320,000 after acquiring an additional 753 shares during the period. Rhumbline Advisers lifted its holdings in shares of Fresenius Medical Care by 6.7% in the 2nd quarter. Rhumbline Advisers now owns 18,067 shares of the company’s stock worth $345,000 after acquiring an additional 1,128 shares during the last quarter. Finally, Marshall Wace LLP boosted its position in shares of Fresenius Medical Care by 8.5% during the 2nd quarter. Marshall Wace LLP now owns 15,363 shares of the company’s stock worth $293,000 after purchasing an additional 1,207 shares during the period. 8.37% of the stock is currently owned by institutional investors and hedge funds.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.